A large observational study has reported that semaglutide, a GLP-1 analog widely used to treat diabetes and obesity, significantly lowers the risks of psychiatric hospitalization and illness relapse among people with bipolar disorder. Analysis of Swedish national registry data found that semaglutide use was associated with a 21% reduction in hospitalization risk and a 17% reduction in relapse risk, suggesting it may be used alongside mood stabilizers. Experts view the findings as a positive signal, while emphasizing that further validation through randomized controlled trials (RCTs) is needed before applying them broadly in clinical practice.

1. Exploring the Link Between Metabolic and Psychiatric Disorders 🧬

GLP-1 receptor agonists (GLP-1 RAs) are firmly established as treatments for diabetes and obesity, but academic interest in their effects on the brain and mental health has grown sharply in recent years. Earlier studies reported that GLP-1 use was associated with lower rates of depression, anxiety, self-harm, and substance-use disorders, but its effects in people with bipolar disorder remained largely unexplored. People with bipolar disorder commonly also have obesity or type 2 diabetes, and recurring mood episodes often lead to hospitalization.

The researchers used Swedish national health-register data to follow 14,694 people with bipolar disorder who were prescribed antidiabetic medication between 2009 and 2024 for approximately six years. Of these, 5,200 used a GLP-1 medication.

They applied a within-individual design, in which each patient served as their own control, directly comparing periods of medication use with periods without medication. They also carefully adjusted for many factors that can change over time, including the use of mood stabilizers, antipsychotics, and antidepressants.

"Unlike the initial reports, these GLP-1 medications appear to be safe from a psychiatric perspective." — Mark Taylor, MD (professor and psychiatrist at Griffith University in Australia)

2. Clear Reductions in Hospitalization and Relapse Risk with Semaglutide 📉

During the follow-up period, 5,288 participants were hospitalized for psychiatric reasons at least once. Analysis showed that taking semaglutide was associated with a 21% lower risk of psychiatric hospitalization than not taking it (adjusted hazard ratio, 0.79). Hospitalization risk was also 13% lower when considering GLP-1 medications as a group.

By contrast, the other GLP-1 compounds liraglutide and dulaglutide did not individually produce statistically significant reductions in risk. This may be because the number of users of those medications was relatively small, resulting in insufficient statistical power.

• Semaglutide vs. other GLP-1 medications: Among 1,274 patients who had used both semaglutide and another GLP-1 medication, semaglutide was associated with a 17% lower hospitalization risk than the other GLP-1 medication.
• Relapse risk: The risk of hospitalization for bipolar relapse was also 17% lower with semaglutide use (15% lower for GLP-1 medications overall).
• Excluding early medication effects and substance-use admissions: Even after excluding the first 30 days after treatment began or admissions related to alcohol or drug addiction, semaglutide's reduction in hospitalization risk remained robust at 20–22%.
• Sick-leave days: However, semaglutide did not have a significant effect on the number of psychiatric sick-leave days lasting 14 days or longer.

The researchers speculate that semaglutide may act directly on the brain to regulate neuroinflammation and positively affect the hypothalamic–pituitary–adrenal (HPA) axis, or that it may indirectly help regulate mood through stronger weight-loss effects.

"We do not yet fully understand the direct effects these medications have on the brain, but I got the impression that they may have distinct effects on neuroinflammation and the HPA axis." — Mark Taylor, MD

3. Study Limitations and the Need for Future Clinical Research 🔬

Although this study found a valuable signal in a large dataset, its observational nature creates several limitations. It is difficult to completely rule out residual confounding, such as the possibility that worsening psychiatric symptoms made patients less likely to start or continue semaglutide treatment.

"We cannot rule out the possibility that worsening psychiatric symptoms made patients less likely to be prescribed semaglutide, or that treatment was maintained mainly among patients who were already receiving good care." — From the research paper

The data also did not include changes in each patient's weight, glycated hemoglobin (A1c), or body mass index (BMI), so it was not possible to clearly determine how much improved metabolic health itself contributed to psychiatric outcomes.

Experts describe the finding as a highly interesting early signal, but caution against premature clinical application.

"The publication of a single report does not mean we are ready to apply semaglutide broadly as a treatment for bipolar disorder. The early signal points to the need for head-to-head comparative studies, and direct clinical trials are essential to establish treatment response clearly." — Steve Strakowski, MD (professor of psychiatry at Indiana University School of Medicine)

4. Conclusion 💡

This study presents an interesting and promising possibility: semaglutide could become an adjunctive treatment option for people with bipolar disorder who also have obesity or type 2 diabetes, helping reduce psychiatric hospitalization and relapse. Although precise verification through randomized controlled trials (RCTs)—covering symptom control, hospitalization rates, and mortality—is needed before it can be introduced as an established treatment, the finding suggests that metabolic-disease medications may help stabilize the lives of people with severe mood disorders.